Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
RecruitingObservational study
Prospective Analysis of Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Who can join
Ages 60 and older · All sexes
Full eligibility criteria
Eligibility Criteria Arm A: * Age 60 years or older. * New diagnosis of Acute Leukemia or MDS, or suspected diagnosis. * Able to consent to the study. Eligibility Criteria Arm B: * Age 60 years or older with a hematologic malignancy. * Plan to undergo an allogeneic blood or marrow transplantation or CAR T-cell therapy. * Able to consent to the study.
About the study
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
What is being tested
- Bone Marrow or Peripheral Blood Graft (BMT) (procedure)
- Cancer-directed Therapy or Best Supportive Care (other)
- Frailty Assessment (diagnostic test)
Sponsor: Abramson Cancer Center at Penn Medicine · Participants: 20 · Started: Sep 21, 2018
Contact the study team
- Shannon McCurdy, MD · Phone: 855-216-0098
Official record on ClinicalTrials.gov — NCT03680677
Locations in the U.S.
| Pennsylvania | Abramson Cancer Center of the University of Pennsylvania, Philadelphia |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.